Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more
Green Cross Lab Cell Corporation (144510) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.015x
Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has a cash flow conversion efficiency ratio of 0.015x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.67 Billion) by net assets (₩431.56 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Green Cross Lab Cell Corporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Green Cross Lab Cell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C6K0
F:C6K0
|
-0.179x |
|
Limes Schlosskliniken AG
XETRA:LIK
|
0.135x |
|
KENGIC Intelligent Technology Co. Ltd. A
SHG:688455
|
N/A |
|
Inogen Inc
NASDAQ:INGN
|
0.011x |
|
FERRO SA ZY 1
F:0MN
|
N/A |
|
MN Holdings Berhad
KLSE:0245
|
0.307x |
|
LITALICO Inc.
F:9N0
|
N/A |
|
Imperial Metals Corporation
PINK:IPMLF
|
0.096x |
Annual Cash Flow Conversion Efficiency for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Green Cross Lab Cell Corporation from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩457.79 Billion | ₩11.34 Billion | 0.025x | +265.48% |
| 2023-12-31 | ₩541.48 Billion | ₩3.67 Billion | 0.007x | -94.50% |
| 2022-12-31 | ₩538.46 Billion | ₩66.42 Billion | 0.123x | +163.63% |
| 2021-12-31 | ₩511.00 Billion | ₩23.91 Billion | 0.047x | -75.73% |
| 2020-12-31 | ₩47.17 Billion | ₩9.09 Billion | 0.193x | +3707.58% |
| 2019-12-31 | ₩44.05 Billion | ₩223.04 Million | 0.005x | -50.78% |
| 2018-12-31 | ₩47.72 Billion | ₩490.92 Million | 0.010x | -82.63% |
| 2017-12-31 | ₩48.32 Billion | ₩2.86 Billion | 0.059x | +1059.97% |
| 2016-12-31 | ₩48.10 Billion | ₩-296.65 Million | -0.006x | -103.71% |
| 2015-12-31 | ₩8.96 Billion | ₩1.49 Billion | 0.166x | -- |